Article
Oncology
Menekse Goker, Stephanie Deblaere, Hannelore Denys, Glenn Vergauwen, Eline Naert, Liv Veldeman, Chris Monten, Rudy Van den Broecke, Jo Van Dorpe, Geert Braems, Koen Van de Vijver
Summary: This study investigated the expression of sTILs and PD-L1 in pleomorphic invasive lobular cancer (pILC). It found that sTILs were present in the majority of pILC patients, while PD-L1 expression was not associated with survival improvement.
Article
Medicine, Research & Experimental
Takahiro Hongo, Ryosuke Kuga, Masaru Miyazaki, Noritaka Komune, Takafumi Nakano, Hidetaka Yamamoto, Kensuke Koike, Kuniaki Sato, Ryunosuke Kogo, Kazuki Nabeshima, Yoshinao Oda, Takashi Nakagawa
Summary: The study on PD-L1 expression and TILs in TBSCC cases revealed that PD-L1 expression was associated with worse prognosis, while a high density of CD8(+) TILs was associated with better prognosis. Understanding the tumor immune microenvironment can help predict prognoses and guide the selection of individualized treatment strategies for TBSCC patients.
Article
Oncology
Audree B. Tadros, Varadan Sevilimedu, Dilip D. Giri, Emily C. Zabor, Monica Morrow, George Plitas
Summary: Metaplastic breast carcinoma (MBC) is a rare and aggressive subtype of breast cancer with poorer survival compared to other triple-negative breast cancers. Among MBC patients, those with heterologous mesenchymal subtype had the best survival, while those with squamous subtype had the worst survival. This calls for further research to identify tailored therapies for MBC's unique biology.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Review
Immunology
Xiaoqin Zheng, Wenjie Jin, Shanshan Wang, Huiguo Ding
Summary: Primary liver cancer is a common malignancy in China, with liver transplantation, hepatic tumor resection, and molecular-targeted agents being the main treatments. Liver cancer has a poor survival rate and high recurrence rate, with tumor-infiltrating lymphocytes playing essential roles in its development and prognosis. Various subtypes of T lymphocytes have been studied for their roles and mechanisms in liver cancer.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Liu Yang, Guohong Liu, Yirong Li, Yunbao Pan
Summary: The clinical study of nasopharyngeal carcinoma has shown that tumor-infiltrating lymphocytes (TILs) play a significant role in the development and prognosis of the disease. Recent research has demonstrated the predictive value of TILs subsets for NPC patients and the success of adoptive immunotherapy using anti-tumor TILs. This review evaluates the role of TILs in tumor growth and explores the potential benefits of TILs-based immunotherapy in NPC treatment.
Article
Oncology
Mayuko Nagano, Kanako Saito, Yuji Kozuka, Masako Ichishi, Hiroto Yuasa, Aya Noro, Nao Imai, Mai Shibusawa, Mao Kimoto, Makoto Ishitobi, Yasutaka Tono, Hiroyasu Oda, Mikiya Ishihara, Toshiro Mizuno, Tomoko Ogawa, Naoyuki Katayama
Summary: In this study, a subset of breast cancer tumors were classified as TIL+PD-L1(+) and enriched with suppressive immune subsets, potentially serving as novel immunotherapeutic targets.
Article
Multidisciplinary Sciences
Toru Hanamura, Shigehisa Kitano, Hiroshi Kagamu, Makiko Yamashita, Mayako Terao, Banri Tsuda, Takuho Okamura, Nobue Kumaki, Katsuto Hozumi, Naoki Harada, Takayuki Iwamoto, Chikako Honda, Sasagu Kurozumi, Naoki Niikura
Summary: This study analyzed the association between immune cell fractions in breast cancer tissues and TIL and PD-L1. The results indicate that TILs reflect differences in the immune responses in the tumor microenvironment, and certain immune cell fractions are favorably expressed in the PD-L1 pathway in breast cancer microenvironments.
SCIENTIFIC REPORTS
(2022)
Article
Pathology
Anne Grabenstetter, Achim A. Jungbluth, Denise Frosina, Raza Hoda, Carlos H. Dos Anjos, Sujata Patil, Varadan Sevilimedu, Britta Weigelt, Jorge S. Reis-Filho, Hong Zhang, Tiffany Traina, Mark E. Robson, Edi Brogi, Hannah Y. Wen
Summary: Immunotherapy targeting PD-L1/programmed death-1 may benefit patients with MpBC, with most cases showing PD-L1 positivity in immune cells. However, there is variability in PD-L1 expression rates depending on the assay used. The SP142 assay demonstrates distinct expression patterns compared to E1L3n and 73-10, highlighting the importance of considering assay-specific characteristics in interpreting PD-L1 expression.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2021)
Article
Oncology
Xiangfei Sun, Ping Shu, Yong Fang, Wei Yuan, Qiang Zhang, Jianyi Sun, Min Fu, Anwei Xue, Xiaodong Gao, Kuntang Shen, Yingyong Hou, Yihong Sun, Jing Qin, Xinyu Qin
Summary: The study found that PD-L1 expression is a predictive biomarker for better prognosis of GISTs. Non-gastric GIST patients, especially those with wild-type mutations, may benefit from PD-1/PD-L1 inhibitors.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Peng Sun, Jiehua He, Xue Chao, Keming Chen, Yuanyuan Xu, Qitao Huang, Jingping Yun, Mei Li, Rongzhen Luo, Jinbo Kuang, Huajia Wang, Haosen Li, Hui Hui, Shuoyu Xu
Summary: This study establishes a computational TIL assessment method using deep learning, providing valuable prognostic information for TNBC patients. A three-tier stratification model combining mTIL and aTIL shows a higher C-index, indicating its potential for improved risk management and decision-making by pathologists.
Article
Oncology
Jesse Lopes da Silva, Lucas Zanetti de Albuquerque, Fabiana Resende Rodrigues, Guilherme Gomes de Mesquita, Priscila Valverde Fernandes, Luiz Claudio Santos Thuler, Andreia Cristina de Melo
Summary: This study found that the immune cell subtype in the tumor microenvironment after neoadjuvant chemotherapy can be a determining factor in the prognosis of patients with triple-negative breast cancer.
FRONTIERS IN ONCOLOGY
(2021)
Article
Pathology
Bryce Parkinson, Wei Chen, Tiansheng Shen, Anil Parwani, Zaibo Li
Summary: TRPS1 is a highly sensitive and specific marker for breast carcinomas, and its expression is associated with tumor subtypes and HER2 protein.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2022)
Article
Oncology
Sherene Loi, Roberto Salgado, Sylvia Adams, Giancarlo Pruneri, Prudence A. Francis, Magali Lacroix-Triki, Heikki Joensuu, Maria Vittoria Dieci, Sunil Badve, Sandra Demaria, Robert Gray, Elisabetta Munzone, Damien Drubay, Jerome Lemonnier, Christos Sotiriou, Pirkko Liisa Kellokumpu-Lehtinen, Andrea Vingiani, Kathryn Gray, Fabrice Andre, Carsten Denkert, Martine Piccart, Elvire Roblin, Stefan Michiels
Summary: The importance of integrating biomarkers such as TILs into the TNM staging system for TNBC has been emphasized in the AJCC 8th Edition. Studies show that TILs can significantly influence the traditional pathological staging, suggesting that considering TILs in addition to stage can lead to better outcomes for TNBC patients.
Article
Oncology
Ying Zhong, Fangyuan Li, Sumei Zhang, Zhenli Yang, Xinyu Ren, Xi Cao, Yali Xu, Dan Guo, Yidong Zhou, Feng Mao, Songjie Shen, Qiang Sun
Summary: This study revealed that SDC1 is a key immune-related gene that is highly expressed in triple-negative breast cancer patients. Patients with high SDC1 expression in tumor cells and low expression in cancer associated fibroblasts (CAFs) had worse prognosis and lower tumor-infiltrating lymphocytes (TILs). Additionally, SDC1 was found to regulate the migration of MDA-MB-231 breast cancer cells through a TGFb1-Smad and E-cadherin-dependent mechanism.
CANCER CELL INTERNATIONAL
(2023)
Article
Biochemistry & Molecular Biology
Kaitang Huang, Meiling Hu, Jiayun Chen, Jinfen Wei, Jingxin Qin, Shudai Lin, Hongli Du
Summary: This study analyzed the heterogeneity within tumor immune microenvironment (TIME) subtypes and found associations with prognosis, immune cell composition, genomics, and transcriptomics patterns. The combination of TIL Z score and PD-L1 expression was shown to be a robust method for classifying TIME and predicting response to ICI therapy. The findings provide insight for screening benefited groups in ICI immunotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Chemistry, Analytical
Huai-Hsuan Chiu, Yun-Jung Tsai, Chiao Lo, Ching-Hung Lin, I-Lin Tsai, Ching-Hua Kuo
Summary: This study developed an efficient LC-MS/MS method using an on-bead trypsin digestion procedure to quantify mAb therapeutics. The method showed better sensitivity and reproducibility, making it suitable for real-world analysis of a large number of clinical samples and contributing to personalized mAb treatment.
ANALYTICA CHIMICA ACTA
(2022)
Article
Oncology
Po-Han Lin, Shin-Cheh Chen, Ling-Ming Tseng, King-Jen Chang, Ai-Chu Huang, Kuo-Chih Cheng, Karen Yang, Hui-Chen Wu, Tsu-Yi Chao, Yuan-Ching Chang, Peng-Chan Lin, Wen-Hung Kuo, Wen-Lin Kuo, Ching-Hung Lin, Huo-Mu Chen, Dah-Cherng Yeh, Liang-Chih Liu, Chun-Yu Liu, Ming-Yang Wang, Chiao Lo, Yen-Shen Lu, Chiun-Sheng Huang
Summary: The study found that Asian breast cancer patients with BRCA mutations had a higher risk of developing contralateral breast cancer, especially for BRCA1 mutation carriers with triple-negative breast cancer as their first breast cancer. However, there were no significant differences in relapse-free survival and overall survival between mutation carriers and control patients.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Tom Wei-Wu Chen, Ruru Chun-Ju Chiang, Alex Le Cesne, Yu-Chun Hsieh, Antoine Italiano, Ya-Wen Yang, Nicolas Penel, Wen-Chung Lee, Emmanuelle Bompas, Thibaud Valentin, Philippe Anract, Nelly Firmin, Florence Duffaud, Ann-Lii Cheng, Francoise Ducimetiere, K. Arnold Chan, Jean-Yves Blay
Summary: The study found significant differences in the incidence and clinical characteristics of soft tissue sarcoma (STS) among different geographic and ethnic populations, suggesting that geographic and ethnic factors may play a crucial role in the pathogenesis of STS.
Article
Oncology
Tom Wei-Wu Chen, Chia-Lang Hsu, Ruey-Long Hong, Jen-Chieh Lee, Koping Chang, Chih-Wei Yu, San-Chi Chen, Jhe-Cyuan Guo, Mei-Lu Chen, Meng-Chi Hsu, Ting-Fang Kung, Ann-Lii Cheng, Chueh-Chuan Yen
Summary: The LEADER study investigated the safety and efficacy of lenvatinib in combination with eribulin for the treatment of advanced leiomyosarcoma and liposarcoma. The study showed that this combination therapy has a manageable safety profile and demonstrates promising efficacy.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Wei-Li Ma, Dwan-Ying Chang, Ching-Hung Lin, Kao-Lang Liu, Po-Chin Liang, Huang-Chun Lien, Chan-Chuan Hu, Ling-Yun Huang, Yi-Chun Yeh, Yen-Shen Lu
Summary: Pseudocirrhosis is a common finding in liver metastasis, and its presence can lead to a shorter overall survival in patients with metastatic breast cancer. The presence of esophageal or gastric varices is associated with poorer outcomes in these patients.
Article
Oncology
Ching-Hung Lin, Muhammad Zahid, Wen-Hung Kuo, Ming-Yang Wang, Fu-Chang Hu, I-Chun Chen, Cheryl L. Beseler, Bodhisattwa Mondal, Yen -Shen Lu, Eleanor G. Rogan, Ann-Lii Cheng
Summary: The incidence of breast cancer among premenopausal women in East Asia has been increasing rapidly. This study found that the ratio of estrogen-DNA adducts in plasma was significantly higher in the case group compared to the control group, and it was a significant predictor of breast cancer risk in premenopausal women.
CANCER PREVENTION RESEARCH
(2023)
Article
Multidisciplinary Sciences
Pei-Wen Huang, Hsu Ouyang, Bang-Yi Hsu, Yu-Ruei Chang, Yu-Chieh Lin, Yung-An Chen, Yu-Han Hsieh, Chien-Chung Fu, Chien-Feng Li, Ching-Hung Lin, Yen-Yin Lin, Margaret Dah-Tsyr Chang, Tun-Wen Pai
Review
Public, Environmental & Occupational Health
Joanne Wing Yan Chiu, Soo Chin Lee, James Chung-man Ho, Yeon Hee Park, Ta-Chung Chao, Sung-Bae Kim, Elgene Lim, Ching-Hung Lin, Sherene Loi, Su Ying Low, Lynette Li San Teo, Winnie Yeo, Rebecca Dent
Summary: Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate targeting HER2, has shown improved outcomes for patients with HER2-positive and HER2-low metastatic breast cancer. Monitoring and managing T-DXd-related adverse events (AEs) is a growing need, and experts from the Asia-Pacific region provided recommendations based on clinical trial evidence and regional healthcare considerations. Proactive monitoring and management are crucial for maximizing the benefits of T-DXd.
Review
Oncology
Shang-Hsuan Peng, Ching-Hung Lin, I-Chun Chen, Ying-Chun Shen, Dwan-Ying Chang, Tom Wei-Wu Chen, Shu-Min Huang, Fu-Chang Hu, Yen-Shen Lu
Summary: This systematic review found that Asian patients with advanced cancers may derive superior overall survival benefits from pembrolizumab compared to non-Asian patients. However, no significant difference was found in progression-free survival. The study also identified the open-label design as a key covariate that favored non-Asian participants. These findings provide important insights into clinical research design.
Article
Oncology
Ming-Shen Dai, Ta-Chung Chao, Chang-Fang Chiu, Yen-Shen Lu, Her-Shyong Shiah, Christopher G. C. A. Jackson, Noelyn Hung, Jianguo Zhi, David L. L. Cutler, Rudolf Kwan, Douglas Kramer, Wing-Kai Chan, Albert Qin, Kuan-Chiao Tseng, Cheung Tak Hung, Tsu-Yi Chao
Summary: This study investigated the pharmacokinetics, overall response rate, and safety of weekly oral paclitaxel with encequidar in patients with advanced breast cancer. The results showed that the combination therapy produced consistent therapeutic plasma paclitaxel exposure and had a high clinical benefit rate, with a low rate of neurotoxicity.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)